Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL

Trial Profile

Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 11 Nov 2016 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
    • 11 Nov 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
    • 11 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top